Published: 2020-03-26

Trends in the profile of non hodgkins lymphoma in North and South India: a study from two tertiary care hospitals in India

Rahul Sud, Kishore Kumar, A. P. Dubey, Sagar Bhagat


Background: A number of environmental and chemical factors have been thought to been implicated in the occurrence of Non-Hodgkin’s Lymphomas (NHLs).To fill the knowledge gap in various aspect of the disease, this study was undertaken at this tertiary care centre in Delhi and Bangalore.

Methods: This was a prospective observational study conducted in two defenses medical centre in India among patients of Non Hodgkins Lymphoma, registered at Command hospital Airforce Bangalore and Army Hospital (Research and Referral), New Delhi, between March 2016 and March 2019.

Results: The disease showed a bimodal onset in both centres with 26 (26%) and 24 (24%) cases occurring in the age group of 31-40 years and 24 (24%) and 25 (25%) cases occurring in the age group of >60 years at CHAF (B) and AH (RR) respectively. B cell Lymphoma was the most common type of NHL seen in 85% and 89% patients, whereas T-cell lymphomas constituted 13% and 11% at CHAF (B) and AH (RR).  32(32%) patients presented with an Ann Arbor Stage 1 or 2 disease whereas 68(68%) patients were with Stage 3 or 4 disease at both the centers. IPI score was ≥3 in 45 % and 43% patients.

Conclusions: NHL in India is a homogeneous and uniform disease. But there was increased detection of hepatosplenomegaly and associated hepatitis B/C in the southern part of India. Also, the occurrence of Cutaneous T cell lymphoma was only seen in the south India centre. The early stage NHLs has better survival and increase chance of complete response.


B cell Lymphoma, Cutaneous T cell lymphoma, India, Non-Hodgkins Lymphoma, T-cell lymphomas

Full Text:



Yeole BB. Trends in the incidence of Non-Hodgkin's lymphoma in India. Asian Pac J Cancer Prev. 2008 Jan 1;9(3):433-6.

Mozaheb Z. Epidemiology of Lymphoid Malignancy in Asia, Epidemiology Insight. 2012. Available at: Accessed 21 August 2019.

Shankland KR, Armitage JO, Hancock BW. Non-hodgkin lymphoma. Lancet. 2012 Sep 1;380(9844):848-57.

Wang SS, Vose JM. Epidemiology and Prognosis of T-Cell Lymphoma. T cell Lymphoma. 2012;25-39.

Rosenwald A, Wright G, Chan WC, Connors JM, Campo E, Fisher RI, et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. New Eng J Med. 2002 Jun 20;346(25):1937-47.

Hans CP, Weisenburger DD, Greiner TC, Gascoyne RD, Delabie J, Ott G, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood. 2004 Jan 1;103(1):275-82.

Xing X, Feldman AL. Anaplastic large cell lymphomas: ALK positive, ALK negative, and primary cutaneous. Advan Anatom Pathol. 2015 Jan 1;22(1):29-49.

Juweid ME, Wiseman GA, Vose JM, Ritchie JM, Menda Y, Wooldridge JE, et al. Response assessment of aggressive non-Hodgkin’s lymphoma by integrated International Workshop Criteria and fluorine-18–fluorodeoxyglucose positron emission tomography. J Clin Oncol. 2005 Jul 20;23(21):4652-61.

Cunningham D, Hawkes EA, Jack A, Qian W, Smith P, Mouncey P, et al. Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles. Lancet. 2013 May 25;381(9880):1817-26.

Solal-Céligny P, Roy P, Colombat P, White J, Armitage JO, Arranz-Saez R, et al. Follicular lymphoma international prognostic index. Blood. 2004 Sep 1;104(5):1258-65.

Garg A, Dawar R, Agarwal V, Rustagi RK, Kochupillai V. Non‐Hodgkin's lymphoma in Northern India. A retrospective analysis of 238 cases. Cancer. 1985 Aug 15;56(4):972-7.

Schmitz N, Nickelsen M, Ziepert M, Haenel M, Borchmann P, Schmidt C, et al. Conventional chemotherapy (CHOEP-14) with rituximab or high-dose chemotherapy (MegaCHOEP) with rituximab for young, high-risk patients with aggressive B-cell lymphoma: an open-label, randomised, phase 3 trial (DSHNHL 2002-1). Lancet Oncol. 2012 Dec 1;13(12):1250-9.

Nowakowski GS, LaPlant B, Macon WR, Reeder CB, Foran JM, Nelson GD, et al. Lenalidomide combined with R-CHOP overcomes negative prognostic impact of non–germinal center B-cell phenotype in newly diagnosed diffuse large B-cell lymphoma: a phase II study. J Clin Oncol. 2015 Jan 20;33(3):251-7.

Rosenberg SA. Validity of the Ann Arbor staging classification for the non-Hodgkin's lymphomas. Cancer Treat Rep. 1977 Sep;61(6):1023-7.

Pfreundschuh M, Schubert J, Ziepert M, Schmits R, Mohren M, Lengfelder E, et al. German High- Grade Non-Hodgkin Lymphoma Study Group (DSHNHL). Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20þ B-cell lymphomas: a randomised controlled trial (RICOVER-60). Lancet Oncol. 2008;9(2):105-16.

Xue QY, Chen WH, O'Connell DL. Improved survival for non-Hodgkin lymphoma patients in New South Wales, Australia. BMC Cancer. 2010 Dec;10(1):231.

Mitterlechner T, Fiegl M, Mühlböck H, Oberaigner W, Dirnhofer S, Tzankov A. Epidemiology of non-Hodgkin lymphomas in Tyrol/Austria from 1991 to 2000. J Clin Pathol. 2006 Jan 1;59(1):48-55.

Morschhauser F, Radford J, Van Hoof A, Vitolo U, Soubeyran P, Tilly H, et al. Phase III trial of consolidation therapy with yttrium-90–ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma. J Clin Oncol. 2008 Nov 10;26(32):5156-64.

Dubey AP, Singh R, Pathak A, Viswanath S, Rathore A, Pathi N. Clinicalprofile, prognostication and treatment outcomes in non-Hodgkins lymphoma. Int J Adv Med. 2017;4:1184-8.

Ramani A, Kumar KA, Rao KK, Vidyasagar MS, Kundaje GN. Clinicopathological profile of lymphomas in south India: a prospective rural referral hospital study of 103 cases. J Assoc Phys Ind. 1991;39:322-5.

Chakrabarti S, Sarkar S, Goswami BK, Mondal S, Roy A, Das S. Hodgkin’s and Non-Hodgkin’s Lymphomas in an Indian Rural Medical Institution: Comparative Clinicopathologic Analysis. Asian Pacific J Cancer Preven. 2010;11:1606-8.

Ferraris AM, Giuntini P, Gaetani GF. Serum lactic dehydrogenase as a prognostic tool for non-Hodgkin lymphomas. Blood. 1979;54:928-32.

Moormeier JA, Williams SF, Golomb HM. The staging of non-Hodgkin’s lymphomas. Semin Oncol. 1990;17:43-50.

Rosenwald A, Wright G, Chan WC, Connors JM, Campo E, Fisher RI, et al. Lymphoma/Leukemia Molecular Profiling Project. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med. 2002;346(25):1937-47.

Naresh KN, Srinivas V, Soman CS. Distribution of various subtypes of non-Hodgkin's lymphoma in India: a study of 2773 lymphomas using R.E.A.L. and WHO Classifications. Ann Oncol. 2000; 11(1):63-7.

Skarin AT, Dorfman DM. Non-Hodgkin's Lymphomas: Current Classification and Management. CA-A Cancer J Clin. 1997;47:351-72.